Government Plans 30% Trade Margin Cap on Non-Scheduled Anti-Cancer Drugs, Prices May Drop by 70%

In a landmark move aimed at easing the crippling financial burden of critical healthcare, prices of several life-saving anti-cancer medicines are poised to fall by up to 70 per cent. According to official sources, the central government is actively considering capping trade margins at 30 per cent of the Maximum Retail Price (MRP) for non-scheduled anti-cancer drugs. This transformative policy intervention is projected to save Indian cancer patients an estimated Rs 2,500 crore annually, marking a major leap forward in making oncology treatments accessible, affordable, and patient-centric.

Understanding the 30 Per Cent Trade Margin Cap

The proposed regulation is designed to address excessive trade mark-ups and high retail pricing structures across the pharmaceutical sector:

• Scope of the Policy: The planned price cap will encompass a wide spectrum of anti-cancer medications, including both domestic and imported drugs, generic as well as branded formulations, and both patented and non-patented treatments.

• Targeting High-Cost Medications: By restricting trade margins to 30% of MRP, the intervention will directly target exorbitant mark-ups on high-cost patented therapies, driving down retail prices dramatically for vulnerable families.

Building on Past Success and Healthcare Goals

This initiative follows and expands upon earlier governmental interventions:

• The 2019 Precedent: A similar policy introduced in 2019 successfully generated cumulative annual savings of Rs 984 crore across 526 medicine brands.

• Strengthening Patient Care: The latest proposal builds upon that foundation, reflecting an aggressive push toward affordable healthcare access. A specialized committee—including expert oncologists—has been constituted to review and finalize the pricing framework before formal implementation.

Expected Relief for Patients and Future Outlook

Cancer treatment often involves prolonged financial distress due to the high cost of specialized medications. If formally approved and implemented, this policy will provide immediate relief by drastically lowering retail costs while ensuring uninterrupted supply chains across hospitals and pharmacies. Furthermore, official sources indicate that the government may explore extending similar price-capping mechanisms to other critical care drugs in the future, reinforcing its commitment to universal health affordability.